MICHAEL KLEIN - Corporate Board Profile

ICAD INC

Filing Date	Source Excerpt
2011-06-06	Michael Klein is currently the President at Civco Radiation Oncology Division. ... We believe Mr. Klein’s qualifications to serve on our Board include his understanding of our products and market combined with his executive leadership skills and significant experience as an executive in the healthcare industry. ... The Compensation Committee currently consists of Dr. Sussman (Chairperson), Dr. Brem and Mr. Klein. ... 2010 Non-Employee Director Compensation: Michael Klein total $13,643.
2012-04-09	The Compensation Committee currently consists of, Dr. Sussman, Chairperson, and Dr. Brem and Mr. Klein. The Board of Directors determined that each met the criteria of an independent director under applicable NASDAQ rules.
2013-04-11	The Compensation Committee currently consists of, Dr. Sussman, Chairperson, and Dr. Brem and Mr. Klein. ... 2012 Non-Employee Director Compensation: ... Michael Klein 22,500 Fees earned or paid in cash, 3,063 Option Awards, 25,563 Total.
2018-11-20	Michael Klein Executive Chairman and Interim CEO Mr. Klein’s compensation will consist of an annual base salary of $150,000 and a target annual incentive bonus of 50% of his base salary if the Company achieves goals and objectives determined by the Compensation Committee.
2019-11-08	Michael Klein Chairman and Chief Executive Officer
2020-05-27	Mr. Michael Klein is the Company’s Executive Chairman and Chief Executive Officer. ... Mr. Klein’s compensation consists of an annual base salary of $400,000, and a target annual incentive bonus of 65% of his base salary if the Company achieves goals and objectives determined by the Compensation Committee. ... Summary Compensation Table shows total compensation of $495,370 for 2019.
2021-06-07	Mr. Michael Klein is the Company9s Chairman and Chief Executive Officer. Mr. Klein has served as the Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services, since December 2014. Since 2019, Mr. Klein has served as a member of the board of directors of Avenda Health Care, a medical technology company focused on developing solutions to identify and treat prostate cancer, and since September 2016, he has been a professor of practice at Santa Clara University. Mr. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies, from December 2011 to November 2014. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to the Company in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. Previously, Mr. Klein served in VP, Sales and Marketing Roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. We believe Mr. Klein9s qualifications to serve on our Board include his significant experience as an executive in the healthcare industry, his understanding of our products and markets and his previous tenure on our Board.
2022-05-02	Mr. Michael Klein has served as a Director since December 2018, and previously served as Chairman of the Board from December 2018 to April 2022 and as Chief Executive Officer from December 2018 to March 2022, respectively. ... We believe Mr. Klein 27s qualifications to serve on our Board include his significant experience as an executive in the healthcare industry, his understanding of our products and markets and his previous tenure on our Board.